Louisiana 2012 Regular Session

Louisiana Senate Bill SB239

Introduced
3/12/12  
Refer
3/12/12  
Report Pass
4/18/12  
Engrossed
4/24/12  
Refer
4/25/12  
Report Pass
5/21/12  
Enrolled
6/4/12  
Chaptered
6/12/12  

Caption

Provides the methods of obtaining informed consent and creates the Louisiana Medical Disclosure Panel. (gov sig)

Impact

The passing of SB239 significantly impacts state laws concerning patient rights and medical disclosures. By implementing specific requirements for disclosures tied to informed consent, the bill aims to safeguard patients while also providing a legal framework within which healthcare providers operate. The legislation specifically outlines how informed consent should be documented, emphasizing the need for clarity in communication between medical practitioners and patients. The new regulations aim to prevent legal disputes related to informed consent failures and enhance patient awareness of their health treatment options.

Summary

Senate Bill 239, also known as the Informed Consent and Medical Disclosure Act, introduces essential reforms for how informed consent is obtained in the medical field within Louisiana. The bill establishes a Louisiana Medical Disclosure Panel under the Department of Health and Hospitals that is tasked with developing guidelines for consent related to medical and surgical procedures. One of its primary intentions is to formalize the processes surrounding consent, specifically detailing the necessary disclosures physicians must communicate to patients regarding the risks and hazards associated with treatments.

Sentiment

The sentiment surrounding SB239 is primarily positive from healthcare providers and regulatory bodies who believe that clearer guidelines will improve the quality of care and enhance trust between medical professionals and patients. However, some concerns have been raised regarding the potential for increased administrative burden on healthcare providers, particularly among smaller practices that may struggle with compliance relative to larger healthcare systems. This tension reveals a divided perspective where some stakeholders advocate for regulatory clarity while others fear overregulation might impede healthcare delivery.

Contention

Notable points of contention stem from the bill's provisions regarding the newly formed Louisiana Medical Disclosure Panel, which is granted significant powers to determine not only the necessary disclosures but also the legal implications of non-disclosure. Critics fear that the panel could inadvertently limit physicians' ability to use their professional judgment in uniquely complex medical cases. Additionally, discussions regarding the confidentiality protections for sensitive health information, particularly concerning HIV testing, suggest that while the bill improves transparency, it might also raise new concerns about the balance between consent and patients' privacy rights.

Companion Bills

No companion bills found.

Similar Bills

LA HB866

Provides relative to informed consent for medical treatment and creates the La. Medical Disclosure Panel

LA HB568

Provides that the regulation of therapeutic cannabis be placed under the authority of the Louisiana Department of Health (EG DECREASE GF EX See Note)

LA SB271

Provides for medical marijuana. (See Act) (RE1 SEE FISC NOTE GF EX See Note)

LA HB627

Authorizes the recommendation of medical marijuana for treating certain health conditions of persons with autism

MD HB119

Public Health - Giving Infants a Future Without Transmission (GIFT) Act

LA HB667

Reorganizes and recodifies the Miscellaneous Health Provisions chapter of Title 40 of the La. Revised Statutes

LA SB143

Enacts Alison Neustrom Act and provides relative to prescribed marijuana for therapeutic uses and the development of rules and regulations by the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners. (gov sig)